FT : Hedge funds struggle as stocks keep behaving like bonds

Hedge funds struggle as stocks keep behaving like bonds
Market-watchers fret that equities and fixed income are becoming more closely linked

Shalin Madan is nervous. After his investment firm Bodhi Tree Asset Management had a tough October, he pored over the market runes. What he saw scared him enough to switch off his automated trading models.

Fort Lauderdale-based Bodhi is a small quantitative firm with just $12m under management that invests in exchange traded funds according to the signals its computer models spit out. Its bearish bets on the global economy were hit hard as markets picked up last month, pushing the fund’s returns into negative territory for the year.

What is worrying Mr Madan is that swaths of the stock market have become more sensitive to movements in bonds, as income-starved investors have been forced to scour equities in the hope of finding companies that throw off reliable streams of cash.

Traditionally, utilities and real estate trusts have been the most sensitive to rising bond yields; because of their steady dividends they are often known as “bond proxies”. But much broader chunks of the stock market becoming de facto fixed-income substitutes has sucked in too much money, according to Mr Madan.

“Bond risk is more like equity risk, and equity risk is more like bond risk,” he said. “As a result, almost every investment factor is becoming bond-linked.”

So far, there are few signs of this autumn’s sell-off in bonds hurting the stock market, aside from the traditional bond proxies. But Marko Kolanovic, head of quantitative strategy at JPMorgan, says there is still “extreme crowding” in the more defensive, bond-like parts of the stock market, as well as in stocks enjoying positive momentum. He said this was evidence of the “prevalence of groupthink . . . across investment strategies”.

The current environment looks “fragile”, agrees Roberto Croce, a portfolio manager at Mellon, highlighting the recent turbulence in fixed income. The rolling 90-day volatility of the US Treasury market — a key indicator for what is arguably the bedrock of the global financial system — has climbed sharply from an all-time low in 2018 to a four-year high last week.

“It’s impossible to know the catalyst, and this market is good at shrugging off bad news. [But] bond market volatility is a good sign of the fragility,” Mr Croce said. “We've seen steadily rising bond volatility this autumn, and that will eventually have an impact on asset prices.”

Something similar happened in early 2018, and then again last autumn, when rising Treasury yields eventually caused stock markets to buckle, in what was dubbed “Red October” by traders. That led to a spate of forced selling by quant funds that respond to swings in volatility, which in turn inflicted losses on many hedge funds, forcing them to ratchet back their positions. By December, markets were sliding.
Market-watchers at Morgan Stanley are also looking on anxiously. Michael Wilson, head of US equity strategy, feels investors should not necessarily interpret the recent rally in asset prices as “a definitively bullish signal on future growth, given how much of it has been due to excess liquidity provisions” from major central banks around the world.

But there are reasons to be optimistic that the recent rise in government bond yields will not lead to a repeat of “Red October”. Despite concerns about crowding, JPMorgan’s Mr Kolanovic estimates that Treasury yields can rise by another one-and-a-half percentage points before they become a potential problem. Aside from the so-called bond proxies, which tend to drop as bond yields rise, such a move higher is actually likely to be positive for the stock market, he argues.

Moreover, equity hedge funds have a neutral exposure to the stock market at the moment, according to JPMorgan, indicating that they are unlikely to be forced to deleverage if markets turn south again.

The monetary policy backdrop is also very different today. At this stage in 2018, the US Federal Reserve was shrinking its balance sheet and preparing its fourth rate increase of the year, while the European Central Bank was ending its own bond-buying programme, lifting the 10-year Treasury yield to a seven-year high above 3.2 per cent in early October. Now it is back below 2 per cent, as both central banks ease policy.

However, Mr Madan is unconvinced. He argues that there is less slack built into market valuations to allow bond yields to rise much further without causing carnage. He reckons a sustained move above 2 per cent in the 10-year Treasury yield might be enough to cause the stock rally to unravel.

Therefore, instead of letting Bodhi Tree’s models trade on autopilot in this more uncertain environment, he has now put a bet on bond-linked stocks getting clobbered. “It could be like a meteor hitting the dinosaurs,” he said.

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
:

  • PDD -21.9%, URBN -15.4%, PAGS -4.8%, ALC -2.2%, CRM -1% (guidance)

Other news:

  • IDYA -10.4% (presents data from ongoing Phase 1/2 clinical trial evaluating the tolerability and preliminary clinical activity of IDE196)
  • ORGO -5.9% (to sell 9 mln shares of its Class A common stock in an underwritten public offering)
  • CRSP -4.7% (announces public offering of 4.25 mln common shares)
  • MGP -3.4% (prices upsized underwritten public offering of 30 mln Class A shares at a public offering price of $31.25 per share)
  • MTZ -2.8% (attributed to block trade pricing)
  • NYMT -2.7% (prices offering of 25 mln shares of common stock at for gross proceeds of $152.5 mln)
  • AEO -2.4% (following URBN results)
  • MSEX -2.2% (prices offering of 661,157 shares of its common stock at a price to the public of $60.50 per share)
  • BABA -1.4% (prices global offering of 500 mln ordinary shares at approximately $180 per ADS)

Analyst comments:

  • AMRN -6.5% (initiated with Underperform at Oppenheimer; tgt $7)
  • RIG -2.4% (initiated with a Sell at Deutsche Bank)
  • CBOE -1.3% (downgraded to Neutral from Buy at Goldman and removed from Conviction Buy List)
  • ASH -1.3% (downgraded to Market Perform from Outperform at BMO Capital Markets)
  • KSS -0.9% (downgraded to Neutral from Buy at Goldman)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
:

  • AVID +15.3%, TGT +9.3%, QIWI +4.2%, MFGP +3.8%, LOW +3.6%, CURLF +1.5%

Other news:

  • ARAV +215.5% (new positive data from the ongoing Phase 1b portion of the Phase 1b/2 clinical trial of AVB-500 in platinum-resistant recurrent ovarian cancer patients)
  • BRY +24.4% (attributed to comments from California Governor Gavin Newsom that he has ordered a halt to new fracking permits)
  • CRC +12.9% (does not expect yesterday's proposal by the California Department of Conservation to have a significant effect on its production, plans or reserves)
  • MYOV +10.3% (continued strength)
  • FLNT +9.2% (authorizes the repurchase of up to $5 mln shares of common stock)
  • BCRX +6.7% (Point72 increases passive stake)
  • ENDP +6.1% (announces FDA acceptance of BLA for collagenase clostridium histolyticum in patients with cellulite)
  • STNG +3.5% (announced its President Robert Bugbee purchased call options on 200,000 common shares (or 2,000 call option contracts) with strike price of $32.00 and an expiration of January 2020 for the consideration of $450,000)
  • SAFE +2.1% (upsizes offering by 1 mln shares and prices offering of 3 mln shares of common stock at $34.00 per share)

Analyst comments:

  • XCUR +8.8% (initiated with a Buy at Guggenheim)
  • CTMX +8.7% (initiated with a Buy at Guggenheim)
  • I +8.4% (upgraded to Outperform from Mkt Perform at Raymond James)
  • PAYC +0.8% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)

>>> US Early premarket gappers

Early premarket gappers

  • Gapping up:
    • FLNT +16.2%, AVID +15.3%, MYOV +14.9%, TGT +9.4%, IDYA +8.5%, ENDP +8.1%, BCRX +7.2%, LOW +5.4%, QIWI +4.7%, AXNX +4%, CTMX +3.7%, STNG +1.9%, CURLF +1.5%,
  • Gapping down:
    • PDD -19.1%, URBN -16.7%, ORGO -5.9%, AMRN -5.9%, CRSP -5.8%, PAGS -5.1%, MGP -3.3%, NYMT -3%, AEO -2.9%, ALC -2.6%, MSEX -2.2%, RIG -1.5%, BABA -1.5%, MTZ -1.4%, QTT -0.7%, SPG -0.5%

FT : Meat alternatives/China: a swine thing

Meat alternatives/China: a swine thing
Size estimates of the plant-based meat products market in the next decade suggest opportunities in China exist but could easily end up a niche for hipsters

Will plant-based pork dumplings become the faux burgers of China? That is the hope of two US-based meat alternative companies. Impossible Foods plans to enter the world’s largest meat market with plant-based pork. Beyond Meat plans to start production in Asia late next year. China’s meat producers have started launching their own alternative meat. Shares have soared. But all are gambling on untested demand.

The timing seems right. The African swine fever epidemic has almost halved China’s herd. Supply of pork is expected to stay under pressure for at least five more years. A trade war with the US, the biggest pork exporter, has pushed prices higher. Shares of meat processing company Jinzi Ham and local rival MYS Group have rallied on plans to launch plant-based meat. Pea protein manufacturer Yantai Shuangta Foods’ shares are up 165 per cent this year. The market value of China's WH Group, whose US-based pork producer Smithfield Foods has launched a plant-based meat brand, is up 48 per cent. 

But unlike the US, appetite for the new meat substitutes is weak in China. China already has an array of soy-based meat alternatives and tofu dishes for its vegan Buddhists. Outsiders may also vastly underestimate how crucial traditional pork is for Chinese cuisine. It would be difficult to replicate the texture of delicacies like pig fat, feet and brains.

This could explain why WH Group trades at 12 times forward earnings and MYS Group at 18, well below Beyond Meat’s over 270 times. Concerns about an immediate profitability crisis from rising pork prices will outweigh the hopes for alternative meat sales. This year, profit margins have turned negative at Jinzi Ham. Revenues at Yantai have declined almost a fifth in the past year.

The market for plant-based meat products could exceed $140bn in the next decade, estimates Barclays. That size suggests opportunities in China exist but could easily end up a niche market for hipsters. Even then, a flood of start-ups will keep share prices in check.